Veriheal

MARCH 1, 2022

The first legal psilocybin therapy program to take shape in America is slowly progressing in Oregon. Kate Brown conducts regularly scheduled monthly meetings with a goal of shaping the nation’s first Psilocybin therapy program. Oregon’s Psilocybin Therapy Program: Advisory Board Hard at Work. What is Psilocybin?

Therapy 98

Therapy Programs Microdosing Medicine 98

Cannabis Law Report

DECEMBER 9, 2021

08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. as medical consultants to the Company’s DMT stroke clinical research program. In addition to his consulting and directorial responsibilities, he maintains an active research program directed towards improving outcomes for stroke patients. Published: Dec 08, 2021.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

SpeedWeed

APRIL 9, 2021

Although this survey is specifically focused on Texas’ medical marijuana program, it also supports other research showing that cannabis can serve as an effective replacement for pharmaceuticals. The post 61% of Medical Cannabis Users in Texas Said Weed Helped Them Get off Pharmaceuticals appeared first on SpeedWeed.

Pharmaceutical 52

Pharmaceutical Chronic Pain Programs Patients 52

Cannabis Law Report

AUGUST 6, 2021

Rosa Volio said the proposed law could spark development of the pharmaceutical industry, and pre-market value chains starting in agriculture. Those licenses would only be available to organizations such as cantonal agricultural centers, associations of small and medium producers, cooperatives and indigenous development associations.

Hemp 105

Hemp Programs Agriculture Environment 105

Veriheal

MAY 31, 2022

With a worsening opioid situation and an emerging acceptance of medical cannabis, the Lone Star State has a unique opportunity to develop a successful medical marijuana (MMJ) program for its millions of residents battling chronic pain and numerous other conditions. Vital Changes to Texas’ Medical Cannabis Program. More Telemedicine.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Marinus Pharmaceuticals, Inc. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JULY 5, 2021

The ERP implementation takes between 4 to 6 months of installation and programming and. pricing, you will lose money due to poor programming. It is important to consider that the system needs to be validated after. implementation, and this is normally not completed by the supplier of the ERP, rather by. independent verification.

Pharmaceutical 111

Pharmaceutical Data Access Business 111

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our 917 280 2424 / 401 500 6570.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JUNE 23, 2021

In addition to the pilot program, the parties are working toward an exclusive, definitive supply and distribution agreement, which, if entered into, is expected to position Medicann as the sole supplier and distributor of the RYAH Smart Dry Herb Inhalers in the region. to reach 3.2 billion euros ($3.75 billion) by 2025. 310.299.1717 Office.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

APRIL 15, 2021

PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company,… Read More. TORONTO, April 15, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd.

Programs 45

Programs Pharmaceutical Cannabis 45

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Aggregated Safety and Tolerability Experience from the Ganaxolone Development Program. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. ET (12:00 p.m.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Project CBD

JULY 28, 2023

You need access to sophisticated analytical methods to discern product purity from the isomeric byproducts formed, which is why production from hemp-derived cannabinoid products needs to be done under the appropriate FDA regulations for API [active pharmaceutical ingredient] synthesis and manufacturing.

THC 212

THC Cannabinoids Hemp Research and Development 212

SpeedWeed

JUNE 14, 2021

State officials tasked with overseeing Ohio’s medical marijuana program approved last week the addition of three health conditions that qualify a patient to use cannabis medicinally. The addition of all three, new, medical conditions to the Ohio Medical Marijuana Control Program (OMMCP) is effective immediately. View original article.

Conditions 40

Conditions Programs Therapy Patients 40

Cannabis Law Report

OCTOBER 28, 2021

. “This investment will see Greenlab’s researchers carrying out rigorous trials and lab testing at its leased facilities at Lincoln University to ensure a consistently high-quality and effective pharmaceutical product.”

Programs 52

Programs Research and Development Pharmaceutical Cultivation 52

Cannabis Law Report

SEPTEMBER 8, 2021

Shoppers Drug Mart, Canada’s largest retail pharmacy chain, currently uses the TruTrace platform as its underpinning technology infrastructure for traceability and accountability associated with its medical cannabis program. That tag is then tested at key nodes within a domestic or international supply chain.

Supply Chain 95

Supply Chain Pharmaceutical Seed-To-Sale Events 95

NORML

MAY 26, 2020

Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models.” Chronic pain is the most commonly reported qualifying condition among medical cannabis patients enrolled in state-specific access programs.

Clinical Trials 252

Clinical Trials Chronic Pain Cannabinoids Patients 252

Cannabis Law Report

AUGUST 27, 2021

.’s (NASDAQ: ACB ) (TSX: ACB ) subsidiary Aurora Germany GmbH and Ethypharm have delivered their initial shipment of cannabis to the French medical cannabis pilot program. If successful, this pilot program could lead to one of the largest regulated medical cannabis markets in Europe.”

Patients 105

Patients Programs Pharmaceutical Compliance 105

Cannabis Law Report

FEBRUARY 7, 2023

Under this new program, Protonify will provide cannabis researchers with complimentary access to its high-purity, pharmaceutical-grade cannabinoid ingredients including THC concentrate and THCA isolate.

Pharmaceutical 52

Pharmaceutical Cannabinoids Concentrates THC 52

Cannabis Law Report

JUNE 6, 2022

TRC Healthcare (TRC) has launched a new training program to help pharmacists deliver better healthcare for patients who use cannabis products. The online program, known as RxAdvanced: Guide to Cannabis , gives pharmacists a foundational knowledge of cannabis that strengthens their role as stewards of public health. “As Press Release.

Education 52

Education Research and Development Pharmaceutical Programs 52

NORML

JULY 1, 2019

Three new laws intended to expand patient access to and the therapeutic value of Virginia’s medical cannabis program take effect July 1, 2019. “This year, my focus was on program improvements to further expand both access and therapeutic value to benefit the health and well-being of all Virginians.”

Law 262

Law Patients Access Oil 262

MMJ Recs

NOVEMBER 17, 2023

The community impact is visible in several key areas: Healthcare Advancements MMJ has expanded the range of treatment options available to patients, offering an alternative to conventional pharmaceuticals. The state’s program has evolved to meet the needs of patients and the demands of the industry.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

AUGUST 29, 2021

The export to Brazil also confirms the regulatory pathway and acts as a proof of concept in the largest market in South America where we aim to establish long-lasting supply relationships with our Brazilian pharmaceutical partners.”. 1 Source: Passport, Euromonitor International, Cannabis in Latin America, July 2021.

Extraction 98

Extraction Supply Chain Research and Development CBD 98

Cannabis Law Report

OCTOBER 12, 2021

Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others. Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a pooled COVID-19 testing program that is grounded in the Company’s EUA-authorized Linea™ COVID-19 Assay Kit.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 27, 2021

NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S.,

Research and Development 98

Research and Development Pharmaceutical Sativa Extraction 98

Cannabis Law Report

JULY 28, 2021

The sol-gel technology is designed to deliver pharmaceutical compounds as a liquid at room temperature which becomes a gel at body temperature. UniQuest is a partner on the MRFF Biomedical Translation Bridge (BTB) Program with MTPConnect. Under the terms of the license, InnarisBio will receive exclusive rights in their desired fields.

Research and Development 98

Research and Development Programs Treatment Media 98

Cannabis Law Report

SEPTEMBER 4, 2021

( NEO:FH ) (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development company, today announced that it has filed its 20th patent application in support of the Company’s research phase programs. These filings include three international Patent Cooperation Treaty (PCT) patent applications.

Research and Development 103

Research and Development Extraction Pharmaceutical Programs 103

Cannabis Law Report

NOVEMBER 23, 2021

SOMAÍ Pharmaceuticals Unipessoal LDA, or SOMAÍ, recently received an “innovative products” grant of 2.7 Provided by the Portugal 2020 committee, the grant will help Somaí continue its mission of developing high-quality and efficacious cannabis pharmaceuticals for the European market. million euros ($3.07 Portugal 2020.

Pharmaceutical 52

Pharmaceutical Research and Development Cannabinoids Extraction 52

Cannabis Law Report

AUGUST 7, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency. Full Job Description.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

JULY 29, 2021

With Avicanna’s dedication to quality standards and pharmaceutical positioning we are poised to be a significant long-term player in the European medical market that is predominantly focused on medical utility of cannabinoids and where meeting EU pharmacopeia standards are essential.”.

Extraction 98

Extraction Supply Chain THC Research and Development 98

Cannabis Law Report

JUNE 11, 2021

NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Here’s the press release. NEW YORK, June 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. Rahn will advise the Company during its leadership transition.

Clinical Trials 95

Clinical Trials Research and Development Pharmaceutical Medicine 95

Veriheal

MAY 17, 2021

Many of them even offer the ability for visiting medical cannabis patients from other states to participate in their programs. Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” ” State Doctors Oppose Legalization in Alabama.

Legalization 86

Legalization Pharmaceutical Therapy Chronic Pain 86

Cannabis Law Report

JULY 26, 2021

Dr. Tyle brings over 35 years of experience in the pharmaceutical industry, with over 37 years in senior executive leadership positions encompassing research and development, clinical development, manufacturing, regulatory, business development and operations as well as roles as a board director and scientific advisory board member.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

MMJ Recs

MARCH 23, 2024

Efforts to promote equity in the cannabis industry include initiatives such as social equity programs and the expungement of past cannabis-related convictions, aiming to provide opportunities for inclusion and economic empowerment. The focus is on rectifying past injustices and ensuring fair opportunities in the emerging cannabis industry.

Legalization 52

Legalization Access Programs Education 52

The Cannigma

DECEMBER 4, 2022

THC in 2013 but did not establish a national program. Another draft law was introduced in 2019 to expand the program; as of 2022, it was still in draft in a chamber of government. People who are caught with cannabis for personal use can avoid jail time by participating in an “ integrated assistance program.” Possible penalties.

Law 59

Law Seed-To-Sale Programs Tincture 59

NORML

FEBRUARY 14, 2019

” SB1719, which passed unanimously through both the House of Delegates and Virginia Senate, will also allow Virginia’s licensed pharmaceutical processors to transfer products between the five state-authorized facilities, ensuring that patients have access to a wider range of products. “I am proud to be part of this effort.”

Access 201

Access Patients Legislation Medicine 201

The Cannigma

JUNE 25, 2022

Poland established a medical cannabis program in 2017, which allows for a range of cannabis products to be prescribed for a range of medical conditions. Poland’s medical cannabis program. Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products.

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

The Cannigma

JUNE 1, 2021

France’s (experimental) medical cannabis program. In March, 2021, France launched a two-year experiment to gauge the effectiveness of a nationwide medical marijuana program and to prepare the ground for future distribution, according to the Health Ministry. Shutterstock. Some 170 hospitals will participate in the two-year experiment.

Law 113

Law Epilepsy Programs Patients 113